{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T19:39:30Z","timestamp":1769974770827,"version":"3.49.0"},"reference-count":42,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Novel treatment modalities comprising immune checkpoint inhibitors and targeted therapies have revolutionized treatment of metastatic melanoma. Still, some patients suffer from rapid progression and decease within months after a diagnosis of stage IV melanoma. We aimed to assess whether genomic alterations may predict survival after the development of stage IV disease, irrespective of received therapy. We analyzed tumor samples of 79 patients with stage IV melanoma using a custom next-generation gene-sequencing panel, MelArray, designed to detect alterations in 190 melanoma-relevant genes. We classified the patients: first, as short survivors (survival \u22646 months after stage IV disease, n = 22) and long survivors (survival &gt;6 months, n = 57); second, by using a cut-off of one year; and third, by comparing the longest surviving 20 patients to the shortest surviving 20. Among analyzed genes, no individual gene alterations, or combinations of alterations, could be dichotomously associated with survival. However, the cohort\u2019s mutational profiles closely matched three known mutational signatures curated by the Catalog of Somatic Mutations in Cancer (COSMIC): UV signature COSMIC_7 (cosine-similarity 0.932), clock-like signature COSMIC_5 (cosine-similarity 0.829), and COSMIC_30 (cosine-similarity 0.726). Patients with UV signature had longer survival compared to patients with clock-like and COSMIC 30 (p &lt; 0.0001). Subgroup dichotomization at 6 months showed that 75% of patients with UV signature survived longer than 6 months, and about 75% of patients with clock-like signature survived less than 6 months after development of stage IV disease. In our cohort, clock-like COSMIC_5 mutational signature predicted poor survival while a UV signature COSMIC_7 predicted longer survival. The prognostic value of mutational signatures should be evaluated in prospective studies.<\/jats:p>","DOI":"10.3390\/cancers15153818","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T02:08:00Z","timestamp":1690510080000},"page":"3818","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2999-6388","authenticated-orcid":false,"given":"Fabienne","family":"Fr\u00f6hlich","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8262-8608","authenticated-orcid":false,"given":"Egle","family":"Ramelyte","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3695-8264","authenticated-orcid":false,"given":"Patrick","family":"Turko","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1776-1928","authenticated-orcid":false,"given":"Andreas","family":"Dzung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6874-9649","authenticated-orcid":false,"given":"Sandra N.","family":"Freiberger","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-7575","authenticated-orcid":false,"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5902-9420","authenticated-orcid":false,"given":"Mitchell P.","family":"Levesque","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2279-6906","authenticated-orcid":false,"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, 8091 Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, 8091 Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.11.009","article-title":"TERT Promoter Mutations Are Associated with Longer Progression-Free and Overall Survival in Patients with BRAF-Mutant Melanoma Receiving BRAF and MEK Inhibitor Therapy","volume":"161","author":"Thielmann","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus Investigator-Choice Chemotherapy for Ipilimumab-Refractory Melanoma (KEYNOTE-002): A Randomised, Controlled, Phase 2 Trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival with Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A Phase II Multicenter Study of Ipilimumab with or without Dacarbazine in Chemotherapy-Na\u00efve Patients with Advanced Melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Investig. New Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant Ipilimumab versus Placebo after Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A Randomised, Double-Blind, Phase 3 Trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus Chemotherapy in Patients with Advanced Melanoma Who Progressed after Anti-CTLA-4 Treatment (CheckMate 037): A Randomised, Controlled, Open-Label, Phase 3 Trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e004509","DOI":"10.1136\/jitc-2022-004509","article-title":"Impact of Radiotherapy and Sequencing of Systemic Therapy on Survival Outcomes in Melanoma Patients with Previously Untreated Brain Metastasis: A Multicenter DeCOG Study on 450 Patients from the Prospective Skin Cancer Registry ADOREG","volume":"10","author":"Franklin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.21.02961","article-title":"Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12967-020-02458-x","article-title":"Impact of Initial Treatment and Prognostic Factors on Postprogression Survival in BRAF-Mutated Metastatic Melanoma Treated with Dacarbazine or Vemurafenib \u00b1 Cobimetinib: A Pooled Analysis of Four Clinical Trials","volume":"18","author":"Ascierto","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.soc.2010.09.007","article-title":"Staging and Prognosis of Cutaneous Melanoma","volume":"20","author":"Dickson","year":"2011","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final Version of 2009 AJCC Melanoma Staging and Classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","article-title":"Three-Year Pooled Analysis of Factors Associated with Clinical Outcomes across Dabrafenib and Trametinib Combination Therapy Phase 3 Randomised Trials","volume":"82","author":"Schadendorf","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/S0959-8049(17)30482-3","article-title":"1141\u2014Impact of Baseline Serum Lactate Dehydrogenase Concentration on the Efficacy of Pembrolizumab and Ipilimumab in Patients with Advanced Melanoma: Data from KEYNOTE-006","volume":"72","author":"Long","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e2126337","DOI":"10.1001\/jamanetworkopen.2021.26337","article-title":"Assessing the Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients with Melanoma Using Pathologic Features Identified by Natural Language Processing","volume":"4","author":"Yang","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gide, T.N., Pires da Silva, I., Quek, C., Ferguson, P.M., Batten, M., Shang, P., Ahmed, T., Menzies, A.M., Carlino, M.S., and Saw, R.P.M. (2021). Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +\/\u2212 Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 13.","DOI":"10.3390\/cancers13133186"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","article-title":"European Consensus-Based Interdisciplinary Guideline for Melanoma. Part 2: Treatment\u2014Update 2022","volume":"170","author":"Garbe","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Bafaloukos, D., Gazouli, I., Koutserimpas, C., and Samonis, G. (2023). Evolution and Progress of MRNA Vaccines in the Treatment of Melanoma: Future Prospects. Vaccines, 11.","DOI":"10.3390\/vaccines11030636"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jiang, H., Lei, R., Ding, S.-W., and Zhu, S. (2014). Skewer: A Fast and Accurate Adapter Trimmer for next-Generation Sequencing Paired-End Reads. BMC Bioinform., 15.","DOI":"10.1186\/1471-2105-15-182"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and Accurate Short Read Alignment with Burrows-Wheeler Transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_27","unstructured":"Van der Auwera, G., and O\u2019Connor, B.D. (2020). Genomics in the Cloud: Using Docker, GATK, and WDL in Terra, O\u2019Reilly Media. [1st ed.]."},{"key":"ref_28","first-page":"11.10.1","article-title":"From FastQ Data to High Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline","volume":"43","author":"Carneiro","year":"2013","journal-title":"Curr. Protoc. Bioinform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The Ensembl Variant Effect Predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The Repertoire of Mutational Signatures in Human Cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/php.12377","article-title":"UV Signature Mutations","volume":"91","author":"Brash","year":"2015","journal-title":"Photochem. Photobiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: Mining Complete Cancer Genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_34","unstructured":"(2022, April 01). COSMIC|Mutational Signatures. Available online: https:\/\/cancer.sanger.ac.uk\/signatures\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41591-018-0265-6","article-title":"Ultraviolet Radiation-Induced DNA Damage Is Prognostic for Outcome in Melanoma","volume":"25","author":"Trucco","year":"2019","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.omtn.2020.10.033","article-title":"Association of Clock-like Mutational Signature with Immune Checkpoint Inhibitor Outcome in Patients with Melanoma and NSCLC","volume":"23","author":"Chong","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"CANCER IMMUNOLOGY. The \u201cCancer Immunogram\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-Genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/PO.21.00084","article-title":"Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti\u2013PD-1 Therapy","volume":"5","author":"Dousset","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of Mutational Processes in Human Cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13073-020-00745-2","article-title":"Network-Based Approaches Elucidate Differences within APOBEC and Clock-like Signatures in Breast Cancer","volume":"12","author":"Kim","year":"2020","journal-title":"Genome Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3818\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:20:40Z","timestamp":1760127640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/15\/3818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":42,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15153818"],"URL":"https:\/\/doi.org\/10.3390\/cancers15153818","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]}}}